To investigate the length of time from initial haematuria presentation to upper tract urothelial carcinoma (UTUC) diagnosis and the effect of gender on this duration.
Introduction
The effect of gender on survival outcomes for upper tract urothelial carcinoma (UTUC) is not well understood [1] . While previous studies in patients with UTUC undergoing radical nephroureterectomy (RNU) have shown no difference in cancer-specific survival (CSS) based on gender [2] [3] [4] [5] [6] , there appears to be an association of female gender with inferior CSS [7] [8] [9] . Further support for inferior CSS among female patients comes from studies that show an association of female gender with more advanced-stage disease at the time of RNU [5, 10, 11] , which suggests research is needed to further understand the mechanisms responsible for this gender disparity.
In an effort to elucidate the mechanism of gender differences in urothelial carcinoma of the bladder, Cohn et al. [12] showed that women experienced a longer delay from initial haematuria presentation to bladder cancer diagnosis [12] . While a similar gender-specific delay from haematuria presentation to cancer diagnosis may also occur in patients with UTUC, this has yet to be investigated. Furthermore, with little improvement in survival outcomes for patients with UTUC over the past few decades, one potential target to improve outcomes for these patients is to decrease the time from haematuria presentation to UTUC diagnosis. The aims of the present study, therefore, were to determine how many patients experience a delay in UTUC diagnosis after initial haematuria presentation, the clinical predictors of this delay, and whether gender differences exist with regard to the time from initial haematuria presentation to diagnosis of UTUC.
Patients and Methods

Data Source
The Truven Health MarketScan Commercial Claims and Encounters Database contains encounter and claims data for inpatient and outpatient encounters from~100 privatesector payers throughout the United States [13] . This amounts to linked episodes of healthcare for tens of millions of individuals. We used the 2010-2014 MarketScan Database in an effort to report results reflective of contemporary practice patterns.
Patient Cohorts
Using International Classification of Diseases 9th edition (ICD-9) codes, patients with a diagnosis of UTUC (189.1, 189.2) were identified, and the date of initial diagnosis was determined. So as to exclude cases in which precedent haematuria and UTUC diagnosis may not be related [12] , only individuals with a haematuria claim (599.7, 599.70, 599.71, 599.72) within 1 year of their initial UTUC diagnosis were included. The interval from initial haematuria presentation to cancer diagnosis was defined as the 'evaluation' period. We excluded patients with a pre-existing diagnosis of haematuria or bladder cancer in the year prior to the initial haematuria claim and individuals not enrolled in the MarketScan database 1 year prior to their initial haematuria claim.
To validate our findings, we identified a similar cohort of patients with bladder cancer with a precedent haematuria claim in the year before diagnosis. This was consistent with a previous study of initial haematuria presentation prior to bladder cancer diagnosis conducted in the MarketScan database [12] .
Covariates
Based on previous studies, age at cancer diagnosis was evaluated using a threshold of 59 years (≥59 vs <59 years) [7, 9] . Moreover, the MarketScan database only contains individuals aged <65 years, so 59 years was a reasonable cutoff point to dichotomize the covariate of age. Additional covariates included gender and the type of provider seen at the initial haematuria claim (urologist vs non-urologist). Haematuria was categorized as microscopic, gross or unspecified based on ICD-9 codes (Table S1 ). Using the Deyo version, the Charlson comorbidity index was calculated for all patients using the ICD-9 codes present at the initial haematuria date. Points attributable to cancer diagnoses were excluded because all patients in the cohort had a cancer diagnosis [14] .
Outcome Variables
The primary outcome was the number of days from initial haematuria presentation to UTUC diagnosis. Additionally, a binary outcome of delayed diagnosis was defined as >90 days from initial haematuria presentation to UTUC diagnosis. This threshold was chosen because a 3-month delay in treatment has been shown to be clinically significant in patients with bladder cancer [15, 16] , and this threshold is consistent with previous studies on this topic in bladder cancer [12] . It should be noted that this threshold has not been extensively validated in patients with UTUC; however, previous studies investigating delays from diagnosis to surgery in patients with UTUC have also used 3 months (90 days) as their cut-off point [17, 18] .
In the study cohort of patients with UTUC diagnosis and precedent haematuria, ICD-9 and Current Procedural Terminology codes were used to identify patients who underwent the following tests and procedures: urine analysis, urine culture, abdominopelvic imaging, urine cytology, urinary fluorescence in situ hybridization (FISH), and cystoscopy during the evaluation period (Table S1 ) [12] . Additionally, we identified individuals with claims for UTI, nephrolithiasis and prostate-related diagnoses (prostatitis, BPH, benign prostatic nodule [ Table S1 ]). These diagnoses were chosen because they could lead to the delay of UTUC or bladder cancer diagnosis. Prostaterelated claims that were also present in the year prior to initial haematuria presentation were categorized as 'recurrent' prostate-related diagnosis instead of 'new'. Additionally, encounters that took place with urologists were identified through billing codes.
Statistical Analysis
Individuals in the UTUC study cohort were stratified by gender, and baseline demographic information was compared 378 © 2017 The Authors BJU International © 2017 BJU International between men and women using Student's t-test, the chisquared test and Wilcoxon's rank sum based on the variable distribution. Next, the outcomes of interest mentioned above were compared between men and women in the overall cohort and in these three subsets: (i) patients without prostate-related diagnoses; (ii) patients without UTI diagnosis; and (iii) patients without nephrolithiasis diagnosis. The median and mean number of days from haematuria to UTUC diagnosis and the percentage of patients experiencing delayed diagnosis were compared among patients based on the number and type of benign diagnoses present during their haematuria evaluation and among patients who underwent FISH testing during their evaluation. Then, multivariable Poisson regression models with robust variance estimates were used to identify factors associated with an increased risk of delayed diagnosis (>90 days from initial haematuria presentation to UTUC diagnosis) in the overall cohort. Poisson regression models were used instead of logistic regression because the outcome (delayed diagnosis) had a prevalence of >10%, so the odds ratio would overestimate the risk in logistic regression models. Next, additional multivariable Poisson regression models were created stratified by gender and initial presentation to a non-urologist vs urologist. In an effort to identify the mechanism leading to gender-related disparities, the rates and time to having each of the diagnostic tests performed was compared among men with and without prostate-related and/or nephrolithiasis diagnosis claims, stratified by whether they were seen initially by a urologist or non-urologist. This was repeated comparing patients with prostate-related and/or nephrolithiasis diagnosis claims seen by urologists vs non-urologists.
For validation purposes a similar multivariable Poisson regression model was created to identify factors associated with delayed diagnosis in the bladder cancer cohort. All statistical analyses were conducted in STATA 14 (StataCorp, College Station, TX, USA). All P values reported are twosided with P values ≤0.05 taken to indicate statistical significance. The present study received institutional review board approval from the Johns Hopkins Medical Institution (Baltimore, MD, USA).
Results
In total, we identified 8 734 patients with a UTUC diagnosis. Among them, 74.4% (n = 6 502) were enrolled in the year prior to their UTUC diagnosis. Of these patients, 23 .6% (n = 1 536) presented with haematuria in the year prior to their cancer diagnosis. Next, patients were excluded if they had a haematuria (n = 120) or bladder cancer (n = 90) diagnosis in the year prior to the initial haematuria presentation. This led to a final analytical cohort of 1 326 patients. Of these, 4.4% (n = 58) had a concomitant bladder cancer diagnosis at the time of UTUC diagnosis. The proportion of men in the cohort was 65.3% (n = 866), with a difference in the distribution of haematuria type (P = 0.004) between men and women ( Table 1) . Figure 1 shows the cumulative incidence of days from initial haematuria diagnosis to UTUC diagnosis stratified by gender. Men experienced a significantly longer median duration from haematuria diagnosis to UTUC diagnosis than women (60 [26-139] vs 49 [21-123.5] days; P = 0.04, Table 2 and Fig. 1 ). After exclusion of individuals with a UTI diagnosis, men continued to experience a longer median (53 vs 41 days; P = 0.001) time from initial haematuria to UTUC diagnosis than women (Fig. 1b) . The median number of days from initial haematuria to UTUC diagnosis was also similar in men and women (56.5 vs 48.5 days; P = 0.2) after exclusion of individuals with a nephrolithiasis diagnosis (Fig. 1c) ; however, after exclusion of men with prostate-related diagnoses, the median number of days from initial haematuria to UTUC diagnosis was similar in men and women (51 and 49 [21-123.5] days, respectively; P = 0.8 [ Fig. 1d] ).
Haematuria Evaluation
Women were more likely to have a UTI diagnosis than men (37.0 vs 21.0%; P < 0.001), and 24.4% (211/866) of men had a prostate-associated diagnosis (Table 2 ). There was no difference in the rates of nephrolithiasis diagnosis between men and women (24.5 vs 20.4%; P = 0.1) during evaluation. Men were more likely (P = 0.005) to have a higher number of competing benign diagnoses at the time of their haematuria evaluation. Notably, the percentages of men and women who had a urine analysis, urine culture, cytology, cystoscopy, abdominopelvic imaging and urinary FISH were similar. The median (interquartile range [IQR]) time from initial haematuria diagnosis to being seen by an urologist was similar for men and women (4 [0-15] and 5 [0-21] days, respectively; P = 0.3). For patients with a higher number of competing benign diagnoses present during their evaluation, the median and mean number of days from haematuria diagnosis to UTUC diagnosis were greater, and these patients were more likely to experience a delayed UTUC diagnosis ( Table 3 ).
The mean (SD) and median (IQR) length of time from haematuria presentation to FISH testing was 32 (59.7) and 10.5 (1-29) days, respectively. Patients who underwent FISH testing (n = 128) had a longer time from haematuria diagnosis to UTUC diagnosis than patients who did not (66.5 [35-160] vs 55 days , respectively; P = 0.009) but the percentage of patients experiencing delayed diagnosis was similar in the two groups (41.4 vs 34.7%, respectively; P = 0.1).
Predictors of UTUC Delayed Diagnosis
Factors associated with a delay in diagnosis (>90 days from initial haematuria diagnosis to UTUC diagnosis) were a UTI diagnosis (relative risk [RR] 1.52, 95% CI 1.32-1.76; P < 0.001), nephrolithiasis diagnosis (RR 1.23, 95% CI 1.06-1.44; P = 0.008), new prostate-related diagnosis (RR 1.37, 95% CI 1.12-1.66; P = 0.002), and recurrent prostate-related diagnosis (RR 1.61, 95% CI 1.23-2.10; P < 0.001 [ Table 4 and Fig. 2a-d] ).
When stratified by gender, a UTI diagnosis was associated with delayed diagnosis for both men (RR 1.42, 95% CI 1.19-1.71; P < 0.001) and women (RR 1.72, 95% CI 1.32-2.24; P < 0.001 [ Fig. 2a]) ; however, a nephrolithiasis diagnosis was associated with delayed diagnosis for men (RR 1.28, 95% CI 1.07-1.53; P = 0.007 [ Fig. 2b] ) but not women (RR 1.09, 95% CI 0.81-1.47). Additionally, for men a new prostate-related diagnosis (RR 1.37, 95% CI 1.13-1.67; P = 0.002) and recurrent prostate-related diagnosis (RR 1.57, 95% CI 1.20-2.06; P = 0.001) were associated with delayed diagnosis (Fig. 2c,d ).
When stratified by provider, a nephrolithiasis diagnosis and new and recurrent prostate-related diagnoses were associated with diagnosis delay for patients initially seen by non-urologists (RR 1.25, 95% CI 1.05-1.49; P = 0.01 and RR 1.41, 95% CI 1.12-1.78; P = 0.003 and RR 1.94, 95% CI 1.45-2.58; P < 0.001), but not for patients initially seen by urologists (RR 1.08 95% CI 0.78-1.49; P = 0.6, and RR 1.15, 95% CI 0.79-1.68; P = 0.5 and RR 1.17 95% CI 0.69-1.97; P = 0.6 [ Fig. 2b-d] ). For patients initially seen by urologists (RR 1.74, 95% CI 1.31-2.31; P < 0.001) or non-urologists (RR 1.44, 95% CI 1.22-1.71; P < 0.001) a UTI diagnosis was associated with delayed diagnosis (Fig. 2a) .
Haematuria Evaluation for Men Initially Seen by Non-Urologist vs Urologist
Details of the haematuria diagnosis evaluation for men with vs without prostate-related and/or nephrolithiasis diagnosis during evaluation stratified by whether they were initially seen by a non-urologist or urologist are listed in Table S2a -c. Notably, men with prostate-related and/or nephrolithiasis diagnoses seen by non-urologists were more likely to undergo several of the diagnostic tests (urine analysis, urine culture, abdominopelvic imaging and cystoscopy) than men without prostate-related diagnoses (Table S2a) ; however, cystoscopy and cytology were performed after an increased median interval for men with prostate-related and/or nephrolithiasis diagnoses compared with men without these diagnoses, respectively. Comparing patients with prostate-related and/or nephrolithiasis diagnoses, patients initially seen by non-urologists were more likely to undergo urine analysis, urine culture and abdominopelvic imaging than those seen by urologists (Table S2c) ; however, for patients initially seen by nonurologists multiple diagnostic tests (cytology, cystoscopy and FISH) were performed at an increased median duration after haematuria presentation compared with patients initially seen by urologists.
Bladder Cancer Validation Cohort
In the bladder cancer cohort, women (n = 3 353) had a longer median (IQR) time from initial haematuria diagnosis to cancer diagnosis (34 days; P = 0.004) than men (30 days; n = 8 043). Women were more likely to experience delayed diagnosis (>90 days) than men (22.0 vs 18.2%; P < 0.001). The multivariable Poisson regression analysis showed that female gender (RR 1.24, 95% CI 1.14-1.35; P < 0.001) was associated with increased risk of delayed diagnosis (Table S3) . 
Discussion
We sought to determine the prevalence of delayed diagnosis in patients with UTUC presenting with haematuria in a large, contemporary cohort. To our knowledge, this is the first study to investigate the duration from haematuria presentation to UTUC diagnosis and the potential for genderbased differences in this outcome. The present findings show that in approximately one-third of patients there were >90 days from initial haematuria presentation to UTUC diagnosis, and the median diagnosis interval was prolonged in men compared with women; however, male gender was not independently associated with an increased risk of delayed diagnosis. Factors associated with delayed diagnosis were the presence of benign diagnoses (UTI, nephrolithiasis and prostate-related diagnoses), with a higher number of benign diagnoses being associated with a longer delay before UTUC diagnosis. Furthermore, when stratified by provider at initial haematuria appointment, prostate-related and nephrolithiasis diagnoses were only associated with delayed diagnosis for patients seen by non-urologists at their initial haematuria appointment and not for patients seen by urologists. By contrast, UTI diagnosis was associated with delayed diagnosis for patients initially seen by urologists or non-urologists. Overall, these findings show that benign diagnoses are a major contributor to delayed diagnosis in patients with UTUC, and highlight the need for improved non-invasive diagnostic techniques to improve the clinical risk stratification of patients presenting with haematuria to decrease delays in UTUC diagnosis.
In the present study, we found approximately one-third of patients experienced a delay of >90 days from initial haematuria presentation to UTUC diagnosis. This high rate of delayed diagnosis highlights the need for future research to study the importance of delayed diagnosis in UTUC patients. It is possible that diagnosis delays are contributing to patients having higher-stage or higher-grade disease at the time of definitive treatment, as this association has already been demonstrated in patients with bladder cancer [19] . A recent study by Waldert et al. [18] found that, among patients with muscle-invasive disease (≥pT2), an increased interval from UTUC diagnosis to RNU was an independent predictor of inferior CSS and was also associated with higher-stage disease. Moreover, a recent meta-analysis of prognostic factors in patients with UTUC showed that advanced stage (>pT2) was the strongest predictor of inferior overall survival (hazard ratio 2.62; P < 0.001) [20] . These studies highlight the importance of timely diagnosis and treatment for UTUC in order to maximize the chance of intervening in lessadvanced-stage disease, which is the most important predictor of survival outcomes. Furthermore, in patients with bladder cancer, delay from haematuria presentation to cancer diagnosis was an independent predictor of worse CSS, even after adjustment for disease stage and grade, so it is possible this association also exists in UTUC [21] . The factors associated with delayed diagnosis that we identified could therefore be important targets to improve survival outcomes for patients with UTUC. Overall, the present findings, together with the previous studies mentioned, highlight the need for future research to investigate the effect of delayed diagnosis on disease stage at the time of diagnosis and survival outcomes in patients with UTUC to better understand the clinical relevance of delayed diagnosis in this patient population.
Consistent with findings in the bladder cancer literature [12] , the factors associated with delayed UTUC diagnosis (defined as >90 days) from initial haematuria presentation were having competing benign diagnoses, such as UTIs, nephrolithiasis, and prostate-related diagnoses. As expected, patients with a higher number of benign diagnoses at the time of their haematuria evaluation had a longer time from haematuria presentation to UTUC diagnosis, and they were more likely to experience delayed diagnosis. For men, UTI, nephrolithiasis, new and recurrent prostate-related diagnoses were associated with a 42%, 28%, 37% and 57% increased risk of delayed diagnosis, respectively. For women, a UTI diagnosis was associated with a 72% increased risk of delayed diagnosis, which was almost twice the effect size seen in men. These associations probably arose because the haematuria was attributed to these diagnoses, which delayed further investigation for additional sources of haematuria in these patients. Interestingly, in women, the association of nephrolithiasis with delayed diagnosis was not significant, making this the only benign diagnosis in the present study not associated with delayed diagnosis. This may be because of the small sample size of women with nephrolithiasis in the present study (n = 94) or may also be attributable to the fact that healthcare providers may approach the presence of the same benign diagnosis differently in men and women.
Additionally, we showed that, compared with women, men experienced a significantly longer median time from initial haematuria presentation to UTUC diagnosis. After exclusion of men with prostate-related diagnoses or all patients with nephrolithiasis diagnosis, there was no longer a difference in the median time from initial haematuria to UTUC diagnosis among men and women. These findings suggest the differences in the management of alternative benign diagnoses in men and women (men with prostate-related diagnoses and/or nephrolithiasis diagnosis) may contribute to the longer median time from initial haematuria presentation to UTUC diagnosis observed in men compared with women in the overall cohort. We hypothesize the difference in median time between genders may be because men have a greater number of possible competing benign diagnoses compared with women. Notably, male gender was not associated with the binary outcome of delayed diagnosis in either univariable or multivariable analyses, suggesting the clinical relevance of the increased median time to diagnosis seen in men may be low.
While it is clear that the presence of benign diagnoses is a large contributing factor to delayed diagnosis in patients with UTUC and the gender-based disparity seen in this outcome, potential solutions to decrease the rate of delayed diagnosis are much less clear. One potential area for improvement identified was among patients initially presenting with their haematuria diagnosis to non-urologists as nephrolithiasis and prostate-related diagnoses were only associated with delayed diagnosis in patients seen by non-urologists but not for patients initially seen by urologists. It is important to note that this was not attributable to the inadequacy of the haematuria evaluation of patients seen by non-urologists with nephrolithiasis and prostate-related diagnoses, as these patients were just as likely to undergo diagnostic tests as the patients seen by urologists with nephrolithiasis and prostaterelated diagnoses. However, the patients seen by nonurologists (vs urologists) with nephrolithiasis and/or prostaterelated diagnoses did have a longer duration before undergoing several of the diagnostic tests (cystoscopy, FISH and cytology), which could be a contributory factor and may be a potential area for improvement. Overall, these findings suggest that increasing awareness among non-urologists regarding the presence of delayed diagnosis in patients with haematuria with benign diagnoses may help decrease both the overall rate of delayed diagnosis in this patient population and the gender-based differences observed in the present study.
The major difficulty in decreasing the rates of delayed diagnosis for patients with UTUC lies in the fact that only 3-5% of patients with microhaematuria and 23% of patients with gross haematuria harbour urological malignancies [22] ; therefore, recommendation of an immediate, extensive evaluation of all haematuria cases seen by non-urologists would be very costly for the healthcare system, with minimal improvement in haematuria presentation to UTUC diagnosis times. Notably, the performance of FISH testing was associated with a longer median duration from presentation of haematuria to UTUC diagnosis (66.5 vs 55 days; P = 0.009), suggesting that the test is not used as an initial clinical risk stratification test, but rather in patients with an unclear clinical picture. Ultimately, these challenges highlight the need for better non-invasive, genetic techniques to evaluate the upper urinary tract in patients with haematuria at initial presentation to all providers [23, 24] . The ultimate goal would be to develop novel tests that can improve the clinical risk stratification of these patients on initial haematuria presentation by identifying which patients are in need of urgent urology referral and upper tract evaluation to avoid delays in UTUC diagnosis. Additional factors that probably also contributed to delayed UTUC diagnosis but could not be evaluated in the present study include patient-level factors such as limited access to healthcare, self-misdiagnosis, and poor health literacy. While these factors are outside the direct control of healthcare providers, programmes to improve the general public's understanding of the signs and symptoms of urothelial cancer could prove beneficial.
Importantly, the validation cohort of patients with bladder cancer showed that women were more likely to experience delayed diagnosis (22.0% vs 18.2%) and that female gender was an independent predictor of delayed diagnosis with a 24% increased likelihood of delayed diagnosis compared with men, which is consistent with a previous study conducted using this same database [12] . The consistency of these findings with established literature in the bladder cancer population helps validate the use of these data and our novel results in the UTUC cohort. The finding that women have a longer time from haematuria presentation to bladder cancer diagnosis while men have a longer time from haematuria presentation to UTUC diagnosis is quite interesting, but it is important to realize female gender was an independent predictor of delayed diagnosis in the multivariable model for delayed bladder cancer diagnosis after controlling for confounders, while male gender was not an independent predictor in the multivariable model for delayed UTUC diagnosis. This suggests that the benign diagnoses and other potential confounders included in the model are able to account for the delay in UTUC diagnosis experienced by men, while they cannot account for the delay in bladder cancer diagnosis experienced by women. All benign diagnoses included in the UTUC and bladder cancer cohort multivariable models were associated with a delayed diagnosis, showing that benign diagnoses play an important role in delayed diagnosis for all patients with urothelial carcinoma regardless of site.
The present study has limitations that must be acknowledged. The MarketScan database contains patients with private insurance who were aged <65 years. It is possible that the duration and gender differences found in the present study from haematuria presentation to UTUC diagnosis are either not present or even worse in uninsured patients or individuals with Medicare, and this is an area that warrants future study using other databases. Moreover, the MarketScan database does not provide information on socio-economic status, health literacy, race, smoking history, or an individual's access to healthcare so we could not evaluate the effect of these variables on delayed diagnosis. Additionally, there is no pathological stage information so we could not determine if delayed diagnosis was associated with worse pathological stage at the time of definitive treatment. Also, it is unknown how many of these patients truly had a UTI or prostate-related diagnosis that was contributing to their haematuria. Finally, because of the limitations of the database, we were unable to determine the effect of delayed UTUC diagnosis on survival outcomes, which should be explored in future studies.
In conclusion, the present study is the first to investigate delays in UTUC diagnosis from initial haematuria presentation. More than one-third of patients had >90 days from initial haematuria presentation to UTUC diagnosis, highlighting the need for future studies to better understand the clinical importance of delayed diagnosis on survival outcomes in UTUC patients. Additionally, men had a longer median time from haematuria to UTUC diagnosis compared to women; however, male gender was not a predictor of delayed diagnosis, while all benign diagnoses examined (UTI, prostate-related and nephrolithiasis diagnoses) were associated with delayed diagnosis, especially among patients who initially presented to non-urologists. Overall, these findings highlight the need for improved noninvasive techniques to better screen patients with haematuria, and suggest future interventions should seek to educate practitioners, particularly non-urologists, about the signs of symptoms of UTUC to reduce delays in UTUC diagnosis.
FISH, fluorescence in situ hybridization; IQR, interquartile range.
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